American College of Rheumatology Convergence

Conference Coverage

Q&As

expert Q&A

Difficult-to-Treat Psoriatic Arthritis Characteristics

12/11/2023

Cécile Philippoteaux, MD, MSc, PharmD

In this expert Q&A, Cécile Philippoteaux, MD, MSc, PharmD, discusses the results of her team’s recent review, including the prevalence, characteristics, definition, and the next steps for research in...

12/11/2023

Research Summaries

Conference Coverage

Eosinophilia Common During IL-1, IL-6 Use in Patients With sJIA, non-sJIA

11/30/2022

The researchers examined the incidence rates, risk factors, and outcomes for IL-1 and IL-6 inhibitors in patients with systemic and non-systemic juvenile idiopathic arthritis.

11/30/2022

treatment

Better Clinical Responses Observed With Early Initiation of DMARD Therapy in Treatment of PsA

11/28/2022

Researchers compared if early initiation of disease modifying antirheumatic drugs for the treatment of psoriatic arthritis was superior to later initiation of therapy after diagnosis in a recent study...

11/28/2022

Conference Coverage

Use of IL-6 Receptor Inhibitors Increased in Patients With Adult Still Disease Following Approval of Intravenous Tocilizumab

11/27/2022

Researchers examined the treatment patterns in patients with adult Still disease in clinical practice and assessed changes in oral glucocorticoid dose after tocilizumab administration.

11/27/2022

Genetics

sJIA Linked With Rare Gene Variants in Large-Scale Targeted Sequencing Study

11/23/2022

The researchers set out to determine whether rare variations in certain genes contribute to the risk of developing sJIA.

11/23/2022

management

Manifestations, Outcomes of Adult Onset Still Disease

11/22/2022

To better understand aspects of adult onset Still disease, a rare disorder with complications that may be fatal, researchers examined the various clinical presentations and outcomes associated with the...

11/22/2022

March 2024

Current Issue

March 2024

Volume 64

Issue 3